Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00392886
Recruitment Status : Unknown
Verified October 2010 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : October 26, 2006
Last Update Posted : December 18, 2013
Sponsor:
Information provided by:
National Cancer Institute (NCI)

Tracking Information
First Submitted Date  ICMJE October 25, 2006
First Posted Date  ICMJE October 26, 2006
Last Update Posted Date December 18, 2013
Study Start Date  ICMJE March 2004
Estimated Primary Completion Date December 2010   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 9, 2006)
  • Time to tumor progression, disease recurrence, or death of any cause
  • Event-free survival at 2 years
  • Toxicity
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 9, 2006)
  • Response to induction as assessed by one-time tumor measurements at baseline and after completion of induction chemotherapy
  • Time to death
  • Overall survival
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
Official Title  ICMJE Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]
Brief Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed.

PURPOSE: This phase III trial is studying how well giving combination chemotherapy with or without etoposide followed by an autologous stem cell transplant works in treating young patients with previously untreated malignant brain tumors.

Detailed Description

OBJECTIVES:

Primary

  • Determine the 2-year event-free survival (EFS) and overall survival (OS) of pediatric patients with previously untreated nondisseminated medulloblastoma (< 4 years of age), disseminated medulloblastoma (< 10 years of age), or noncerebellar primitive neuroectodermal tumors (PNET) (disseminated or non-disseminated) treated with induction chemotherapy followed by consolidation with myeloablative chemotherapy and autologous hematopoietic stem cell rescue.
  • Determine the toxicity of this regimen in these patients.
  • Determine the mortality of patients treated with this regimen.

Secondary

  • Determine the complete and partial response rates after completion of induction chemotherapy in these patients stratified according to pathology (medulloblastoma vs noncerebellar PNET vs high-grade gliomas vs atypical teratoid/rhabdoid tumors vs choroid plexus carcinomas and atypical papillomas vs ependymomas).
  • Describe the EFS and OS of these patients stratified according to additional diagnoses (atypical teratoid/rhabdoid tumors vs choroid plexus carcinomas and atypical choroid plexus papillomas vs ependymomas vs high-grade gliomas).
  • Describe the time to progression and patterns of relapse in these patients stratified by diagnosis and radiotherapy received (< 6 years of age with evidence of no residual tumor pre-transplant and no post-transplant consolidation radiotherapy vs < 6 years of age with residual tumor present pre-transplant treated with post-transplant consolidation radiotherapy vs > 6 years of age treated with post-transplant consolidation radiotherapy).
  • Determine the neuropsychometric function, endocrinologic function, and physical growth in these patients stratified according to radiotherapy received (none vs reduced-volume craniospinal radiotherapy vs focused local-field radiotherapy).

OUTLINE: This is a pilot study. Patients are stratified according to type of tumor (nonglial vs glial and diffuse pontine).

  • Regimen C (patients with glial tumors):

    • Stem cell harvesting (bone marrow and/or peripheral blood): Patients undergo leukapheresis or bone marrow aspiration to collect bone marrow or peripheral blood stem cells prior to beginning induction chemotherapy or after the first course of induction chemotherapy.
    • Induction chemotherapy: Patients receive vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Patients with unresectable bulky disease and corticosteroid dependence are removed from study. All other patients proceed to consolidation chemotherapy.

  • Consolidation chemotherapy: Patients receive carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3.
  • Autologous bone marrow or peripheral blood stem cell transplantation: Patients undergo reinfusion of bone marrow or peripheral blood stem cells on day 0. Patients also receive G-CSF SC beginning on day 1 and continuing until blood counts recover.
  • Radiotherapy: Beginning within 6 weeks after stem cell transplantation, patients > 6 years of age at diagnosis undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients ≤ 6 years of age undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.

    • Regimen D2 (patients with nonglial tumors):
  • Stem cell harvesting (bone marrow and/or peripheral blood): Patients undergo leukapheresis or bone marrow aspiration to collect bone marrow or peripheral blood stem cells prior to beginning induction chemotherapy or after the first course of induction chemotherapy.
  • Induction chemotherapy:

    • Courses 1, 3, and 5 (28 days per course): Patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. Patients also receive vincristine IV on days 1, 8, and 15 of courses 1 and 3.
    • Courses 2 and 4 (28 days per course): Patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients also receive vincristine IV on days 1, 8, and 15 of course 2.

Patients with unresectable bulky disease and corticosteroid dependence are removed from study. All other patients proceed to consolidation chemotherapy.

  • Consolidation chemotherapy: Patients receive carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3.
  • Autologous bone marrow or peripheral blood stem cell transplantation: Patients undergo re-infusion of bone marrow or peripheral blood stem cells on day 0. Patients also receive G-CSF SC beginning on day 1 and continuing until blood counts recover.
  • Radiotherapy:Patients undergo radiotherapy as in regimen C. Patients in both regimens undergo neuropsychological testing after induction chemotherapy but before consolidation chemotherapy and then at 18, 36, and 54 months after completion of study treatment. Neuropsychometric and neuroendocrine testing is performed before and after radiotherapy. Quality of life is also assessed periodically.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Primary Purpose: Treatment
Condition  ICMJE Brain and Central Nervous System Tumors
Intervention  ICMJE
  • Drug: carboplatin
    Given IV
  • Drug: cisplatin
    Given IV
  • Drug: cyclophosphamide
    Given IV
  • Drug: etoposide
    Given IV and orally
  • Drug: methotrexate
    Given IV
  • Drug: temozolomide
    Given orally
  • Drug: thiotepa
    Given IV
  • Drug: vincristine sulfate
    Given IV
  • Procedure: autologous bone marrow transplantation
    Given on day 0
  • Procedure: autologous hematopoietic stem cell transplantation
    Given on day 0
  • Procedure: peripheral blood stem cell transplantation
    Given on day 0
  • Radiation: radiation therapy
    Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
Study Arms  ICMJE
  • Experimental: Regimen C
    Patients receive induction therapy of vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients receive consolidation therapy of carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3, undergo reinfusion of bone marrow or peripheral blood stem cells on day 0, and receive G-CSF SC beginning on day 1 and continuing until blood counts recover. Beginning within 6 weeks after transplantation, some patients undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity and some patients undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.
    Interventions:
    • Drug: carboplatin
    • Drug: temozolomide
    • Drug: thiotepa
    • Drug: vincristine sulfate
    • Procedure: autologous bone marrow transplantation
    • Procedure: autologous hematopoietic stem cell transplantation
    • Procedure: peripheral blood stem cell transplantation
    • Radiation: radiation therapy
  • Experimental: Regimen D2
    In courses 1, 3, and 5, patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, vincristine IV on days 1, 8, and 15 (in courses1 and 3), and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. In courses 2 and 4, patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, vincristine IV on days 1, 8, and 15 (in course 2), and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients receive consolidation therapy as in regimen C in combination with etoposide IV over 3 hours on days -5 to -3 and undergo autologous bone marrow or peripheral blood stem cell transplantation, receive G-CSF, and undergo radiotherapy as in regimen C.
    Interventions:
    • Drug: carboplatin
    • Drug: cisplatin
    • Drug: cyclophosphamide
    • Drug: etoposide
    • Drug: methotrexate
    • Drug: temozolomide
    • Drug: thiotepa
    • Drug: vincristine sulfate
    • Procedure: autologous bone marrow transplantation
    • Procedure: autologous hematopoietic stem cell transplantation
    • Procedure: peripheral blood stem cell transplantation
    • Radiation: radiation therapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: November 16, 2006)
120
Original Enrollment  ICMJE Not Provided
Study Completion Date  ICMJE Not Provided
Estimated Primary Completion Date December 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

DISEASE CHARACTERISTICS:

  • Histologically confirmed malignant brain tumor, including any of the following:

    • Posterior fossa medulloblastoma/primitive neuroectodermal tumor (PNET)*

      • All stages allowed
      • Must be < 4 years of age at diagnosis unless there is evidence of postoperative residual tumor (> 1.5 cm² tumor area) or evidence of neuraxis or extraneural dissemination (high-stage)
      • Medulloblastoma, cerebral neuroblastoma, and ependymoblastoma allowed

        • Low-stage (standard-risk) medulloblastoma not allowed in patients > 4 years of age
    • Ependymoma*

      • All stages and locations allowed
      • Cellular and anaplastic subtypes allowed (no myxopapillary ependymomas of the spinal cord)
      • Must be < 36 months of age at diagnosis for posterior fossa tumor OR < 72 months of age for supratentorial tumor
      • Evidence of neuraxis dissemination irrespective of primary site
      • No cellular (low-grade) supratentorial ependymomas at any age with complete resection of parenchymally based (i.e., not periventricular) supratentorial tumors
    • Brain stem tumor*

      • All stages allowed irrespective of extent of resection
      • No unbiopsied diffuse intrinsic pontine tumor
      • Tumor pathologically confirmed to be either malignant glioma or PNET allowed
    • High-grade glioma**
    • Primary atypical teratoid/rhabdoid tumor of the CNS*
    • Choroid plexus carcinoma or atypical choroid plexus papilloma*

      • All stages and locations allowed
    • Anaplastic astrocytoma**
    • Glioblastoma multiforme**
    • Anaplastic oligodendroglioma**
    • Anaplastic ganglioglioma**
    • Other anaplastic mixed gliomas**
    • Small-cell glioblastoma**
    • Giant-cell glioblastoma**
    • Gliosarcoma**
  • The following diagnoses or subtypes are not allowed:

    • Choroid plexus papilloma
    • Pineocytoma
    • Low-grade mixed glioma
    • Primary CNS germ cell tumor
    • Primary CNS lymphoma
    • Solid leukemic lesions (i.e., chloromas, granulocytic sarcomas)
    • Pleomorphic xanthoastrocytoma, low grade
    • Desmoplastic ganglioglioma
    • Low-grade astrocytoma
  • Previously untreated disease
  • Has undergone definitive surgery within the past 42 days NOTE: *Patients receive treatment according to regimen D2

NOTE: **Patients receive treatment according to regimen C

PATIENT CHARACTERISTICS:

  • Bilirubin < 1.5 mg/dL
  • ALT and AST < 2.5 times upper limit of normal
  • Creatinine clearance and/or glomerular filtration rate ≥ 60 mL/min

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior radiotherapy or chemotherapy
  • Prior corticosteroids allowed
  • No concurrent corticosteroids for antiemesis only
  • No concurrent brachytherapy or electron radiotherapy
  • No concurrent dairy products or grapefruit juice with temozolomide administration
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE up to 10 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Canada,   New Zealand,   Switzerland,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00392886
Other Study ID Numbers  ICMJE CDR0000503990
CHLA-HEAD-START-III
CHLA-HSIII
CHLA-2004-020
CHLA-04.020
UMN-MT2004-06
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Jonathan L. Finlay, Childrens Hospital Los Angeles
Study Sponsor  ICMJE Children's Hospital Los Angeles
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Jonathan L. Finlay, MB, ChB Children's Hospital Los Angeles
Investigator: Girish Dhall, MD Children's Hospital Los Angeles
Investigator: Kelley Haley, RN, BSN Children's Hospital Los Angeles
PRS Account National Cancer Institute (NCI)
Verification Date October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP